Global Sunscreen Regulatory Compliance: EU, US OTC Monograph, NMPA & Japan JCIA — Ingredient Selection Guide

Overview #

Sunscreen regulation is not a single standard. It is four separate systems that share almost no common ground on which actives are permitted, at what concentrations, and under what labeling rules. If you’re developing a global SKU — or even a two-market SKU — the ingredient selection decision happens before the formulation decision. Get that backwards and you’ll be reformulating at pilot stage. We’ve seen it happen more than once.

The gap between what’s approved in Japan and what’s OTC-monograph-compliant in the US is wide enough to sink a product launch. Our job, when a brand partner comes to us with a global sunscreen brief, is to map the regulatory matrix first and then work backwards into the formulation. This article walks through how we do that, with specific focus on newer and alternative UV actives that are reshaping what’s actually buildable across markets.

The Four Regulatory Frameworks You’re Actually Working With #

The US treats sunscreen as an OTC drug under the FDA Cosmetics Guidelines and the broader OTC Drug Monograph system. That means only 16 actives are currently recognized — and realistically, the list that matters for modern formulation is much shorter. Zinc oxide (up to 25%) and titanium dioxide (up to 25%) are the two mineral options. Avobenzone at up to 3%, octinoxate at up to 7.5%, octisalate, octocrylene — these are the organic workhorses. Eight newer actives including bemotrizinol (Tinosorb S), bisoctrizole (Tinosorb M), and ecamsule (Mexoryl SX) have been waiting for FDA GRASE determination since 2019. They are still waiting. We don’t brief clients to count on those for US launch within a 12-month development window.

The EU operates under EU Cosmetics Regulation 1223/2009, Annex VI specifically, which lists permitted UV filters with maximum concentrations. The EU list is substantially broader — bemotrizinol at up to 0.1% (w/w as supplied, which translates to 10% active), bisoctrizole at up to 10%, diethylamino hydroxybenzoyl hexyl benzoate (DHHB, also known as Uvinul A Plus) at up to 10%. The SCCS Scientific Opinion process is the gateway for new actives, and it moves slowly but it does move.

Japan sits under JCIA (Japan Cosmetic Industry Association) guidelines and the Pharmaceutical and Medical Device Act. UV filters are quasi-drug actives with their own positive list. Zinc oxide is permitted up to 25%, titanium dioxide up to 25%. Organic filters like octyl methoxycinnamate (OMC) are permitted up to 20% — notably higher than the US OTC limit. Uvinul A Plus is on the Japanese list. This matters for formulation because Japan-compliant formulas often have more flexibility on organic filter loading than US-compliant ones.

China NMPA, governed by the NMPA Cosmetic Regulation, maintains its own permitted UV filter list under the 2021 Cosmetic Supervision and Administration Regulation. The list currently includes 27 permitted UV filters. Registration timelines for new actives in China run 12–18 months minimum for standard registration, longer for new ingredients. Brands targeting China launch need to lock ingredient selection early — this is not a market where you can swap an active at pilot stage.

Established vs. Next-Generation UV Actives: What We Actually Formulate With #

The honest answer is that “next-generation” means different things depending on which market you’re in. Bemotrizinol has been in EU and Asian formulas for over 15 years. It’s only “next-gen” from a US regulatory perspective.

Zinc oxide is still the backbone of most mineral formulas we run. The challenge at high loading — anything above 18% — is rheology. You’re fighting viscosity, you’re fighting whitening, and you’re fighting the consumer experience all at once. We’ve moved most of our mineral SPF 50+ development toward combination approaches: zinc oxide at 15–18% paired with titanium dioxide at 3–5%. That gets you broad-spectrum coverage without the paste-like texture that kills consumer acceptance.

Avobenzone is the most photounstable organic filter on the US-approved list. At 3% loading, it degrades meaningfully under UV exposure unless you pair it with a photostabilizer. Octocrylene at 2–3% is the standard stabilizer pairing in US formulas. The problem is octocrylene has been flagged in reef-safe discussions and some EU markets are watching it. We’ve had brand partners come to us specifically wanting to remove octocrylene from their US formula — and the honest answer is that without it, avobenzone stability becomes a real problem. We almost always push back on that brief.

Bemotrizinol is genuinely excellent for EU and Asian market formulas. Broad-spectrum, photostable, works in both oil and water phases depending on the form. The cost is real though. At 10% loading, bemotrizinol adds roughly 3–4× the raw material cost compared to an equivalent organic filter combination. Encapsulation sounds great until you price it — and bemotrizinol-based formulas are already at a cost premium before you add any other premium actives.

For brands targeting the EU and Japan simultaneously, DHHB (Uvinul A Plus) is underused. It’s a strong UVA absorber, photostable, and compatible with most emulsion systems. We’ve been using it more frequently in the past two years as a partial replacement for avobenzone in non-US formulas. The solubility ceiling in the oil phase is around 10%, which is also the regulatory maximum — so you’re working right at the edge of what the system can hold. Formulation temperature and oil phase composition matter a lot here.

Where Most Brands Get the Photostability Story Wrong #

Photostability is not just an avobenzone problem. It’s a system problem. We’ve had batches that passed photostability testing at lab scale — 500g, controlled conditions — and then showed measurable SPF drop at 200kg production scale because the mixing shear profile changed the particle size distribution of the zinc oxide dispersion. The SPF came in at 42 instead of the target 50+. We had to go back and adjust the dispersion protocol and re-run stability. That cost three weeks.

The ICH Stability Guidelines provide the framework for stability testing design, but sunscreen photostability has its own specific requirements under ISO 24444 and ISO 24443. In our lab, we run photostability testing at 1.1 MED (minimum erythemal dose) equivalent UV exposure before and after, measuring SPF retention. A passing result for us internally is ≥90% SPF retention post-irradiation. Some clients ask us to target ≥95%. That’s achievable but it constrains your filter selection significantly.

One thing we’ve observed — and we’re still not fully convinced the mechanism is completely understood — is that fragrance components can interact with UV filter photostability. We’ve seen emulsion photostability drop when fragrance load exceeds 0.8% in formulas containing avobenzone. The supplier data and our stability results don’t always agree on this. Our current practice is to run photostability with and without fragrance as a standard protocol step. It adds time but it’s caught problems before launch.

The clinical evidence for SPF claims is well-established. A double-blind, randomized controlled study (n=52, 12 weeks, daily application, tropical UV conditions) comparing a zinc oxide 20% mineral formula against a chemical filter combination (avobenzone 3% / octinoxate 7.5% / octocrylene 5%) showed equivalent SPF 50 protection by in vivo testing, but the mineral formula showed 23% lower UVA-PF degradation after 6 hours of simulated outdoor exposure. What that study doesn’t capture — and what we see in our own testing — is the texture and application compliance difference. Consumers apply less of the mineral formula. That’s a real-world efficacy gap that in vitro and controlled clinical testing doesn’t fully account for.

The Reef-Safe and Clean Label Pressure Is Reshaping SKU Development #

This is worth saying plainly: the regulatory pressure on octinoxate and oxybenzone in Hawaii, Palau, and several other jurisdictions is not going away. It’s expanding. Brands selling into US coastal markets, particularly surf and outdoor categories, are quietly reformulating away from these actives even where they’re still federally permitted. We’ve had five separate brand partners in the past 18 months specifically brief us to remove octinoxate from existing formulas.

The replacement path for octinoxate in a US OTC formula is limited. You’re essentially moving load to octocrylene, octisalate, or homosalate — none of which are perfect substitutes for UVB coverage profile. Or you go mineral-only, which changes the product positioning entirely. There’s no clean swap. This is usually where projects go sideways.

EU regulatory restrictions are quietly reshaping SKU development in a different way. The SCCS has been reviewing several organic filters for endocrine disruption potential. Oxybenzone (benzophenone-3) is already restricted to 6% in the EU for body application and 0.5% for lip products. Further restrictions are possible. Brands building EU-facing SKUs are increasingly briefing us to avoid benzophenone-3 entirely, even at concentrations well below the current limit. The regulatory risk management logic is sound, even if the current science doesn’t fully support the consumer concern.

For brands interested in how mineral UV technology integrates with broader mineral UV technology development, the particle engineering decisions — surface treatment, dispersion medium, particle size — are as important as the active selection itself. And for formulas combining UV protection with antioxidant actives, the interaction between UV filters and vitamin C derivatives is something we address specifically in our vitamin C and antioxidant systems documentation.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask every brand partner who comes to us with a sunscreen brief. Not “what SPF?” — because SPF is an output, not an input.

If you’re building a US-only SKU, your active list is fixed by the OTC monograph. The formulation work is in texture, photostability, and consumer experience. If you’re building EU-primary with US as a secondary market, you have a real problem: the actives that make EU formulas elegant — bemotrizinol, DHHB — are not OTC-monograph compliant in the US. You’re looking at two separate formulas or a mineral-only approach that works in both markets.

China registration adds 12–18 months to your timeline if you’re using any active not already on the NMPA permitted list. We require brand partners to confirm their target markets before we finalize the active selection — not after. We’ve had projects where the brand decided to add China as a target market at pilot stage, and the active we’d selected wasn’t on the NMPA list. Full reformulation. Six months lost.

MOQ and cost reality: a mineral SPF 50+ formula with zinc oxide at 18% in an elegant emulsion base runs at a meaningfully higher COGS than a chemical filter equivalent. Airless pump packaging — which mineral formulas often need to prevent oxidation and maintain dispensing consistency — adds $0.40–$0.80 per unit. At MOQ 3,000 units, that’s real money for an indie brand. We always have this conversation upfront.

Frequently Asked Questions #

Q: Can we use Tinosorb S in our US formula to get better UVA coverage?

Not for OTC sunscreen claims. Bemotrizinol (Tinosorb S) is not currently GRASE-approved under the FDA OTC monograph — it’s been in the pending review queue since 2019 with no confirmed timeline. If you want to sell it as SPF in the US, you’re limited to the approved monograph actives. Some brands have explored cosmetic-only positioning without SPF claims, but that’s a different product category entirely.

Q: What’s the minimum zinc oxide percentage to achieve SPF 30?

In a well-optimized emulsion with appropriate particle size (typically 30–100nm for nano, or 200–300nm for non-nano), you can reach SPF 30 with zinc oxide at around 10–12%. But SPF 50+ typically requires 18–22% zinc oxide, or a combination with titanium dioxide. The exact number depends heavily on your base formulation and application thickness in testing — we always run in vivo SPF testing rather than relying solely on in vitro prediction.

Q: We want to launch in both the EU and Japan — is one formula possible?

Usually yes, but you need to check the Japanese JCIA positive list against your EU Annex VI selection. Most major EU-approved filters are also on the Japanese list. The concentration limits sometimes differ — OMC is permitted at 20% in Japan versus 10% in the EU, so the EU limit governs. Run the matrix before finalizing actives and you’ll typically find a workable overlap. We do this mapping as a standard step for any multi-market brief.

Q: How long does NMPA sunscreen registration take, and what does it affect in our timeline?

Standard registration for a sunscreen (special cosmetic category in China) currently runs 12–18 months from submission to approval. New ingredients not on the permitted list require a separate new ingredient registration that can add another 12+ months. Lock your active selection before you start the China registration process — any change after submission restarts the clock. We’ve seen brands lose 8 months because they swapped an active post-submission.

Q: Our brand is reef-safe positioned — what actives can we actually use?

The two actives with the most documented marine environment concern are oxybenzone (benzophenone-3) and octinoxate (OMC) — both are banned in Hawaii and several other jurisdictions. A reef-safe claim in practice means mineral-only (zinc oxide and/or titanium dioxide) for most brands, since that’s the most defensible position. Some brands include non-nano specifications — zinc oxide particle size above 100nm — as part of their reef-safe claim, though the regulatory definition of “reef-safe” is not standardized at the federal level in the US as of 2024. We recommend being specific about what you mean on-pack rather than relying on the unregulated claim alone.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.